Effects of cytotoxic drugs, doxorubicin (adriamycin) and ethidium bromide, on immunoglobulin production have been studied in B-cell hybridomas, myelomas and human lymphocytes. Doxorubicin, and in a lesser extent ethidium bromide, are shown to enhance immunoglobulin production both in drug-resistant and drug-sensitive cell lines. Enhancement of immunoglobulin production is accompanied with that of the number of antibody forming cells and with immunoglobulin synthesis in these cells.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Potential risk factors of protein aggregation in syringe handling during antibody drug dilution for intravenous administration.
J Pharm Sci
January 2025
Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan.
Protein aggregation, a major concern in biopharmaceutical quality control, can be accelerated by various stresses during clinical handling. This study investigated potential aggregation risk factors during dilution process with syringe handling for intravenous administration. Using γ-globulin and IgG solutions as surrogate models of antibody therapeutics, we examined the effects of high sliding speeds and piston operations of the syringe on protein aggregation during saline dilution.
View Article and Find Full Text PDFA biodegradable magnesium alloy promotes subperiosteal osteogenesis via interleukin-10-dependent macrophage immunomodulation.
Biomaterials
December 2024
Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China; Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices& Beijing Key Laboratory of Digital Stomatology & NHC Key Laboratory of Digital Stomatology & NMPA Key Laboratory for Dental Materials, Beijing, China. Electronic address:
In situ bone regeneration and vertical bone augmentation have been huge problems in clinical practice, always imposing a significant economic burden and causing patient suffering. Herein, MgZnYNd magnesium alloy rod implantation in mouse femur resulted in substantial subperiosteal new bone formation, with osteoimmunomodulation playing a pivotal role. Abundant macrophages were attracted to the subperiosteal new bone region and proved to be the most important regulation cells for bone regeneration.
View Article and Find Full Text PDFCOVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers.
Viruses
January 2025
Department of Microbiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
The emergence of new variants and diverse vaccination regimens have raised uncertainty about vaccine effectiveness against SARS-CoV-2. This study aims to investigate the impact of Omicron primo-/reinfection and primary vaccination schedules on the immunogenicity of an mRNA-based booster dose over a six-month period. We conducted a prospective cohort study to assess the durability and level of antibodies of 678 healthcare workers fully vaccinated against COVID-19.
View Article and Find Full Text PDFPolysaccharide Modulates Characteristic Bacteria and Metabolites, Improving the Immune Function of Healthy Mice.
Nutrients
January 2025
State Key Laboratory Incubation Base for Green Processing of Chemical Engineering, School of Chemistry and Chemical Engineering, Shihezi University, Shihezi 832003, China.
Objectives: Polysaccharides from are known to have several bioactive effects. Previous studies have found that low-molecular-weight polysaccharide (GP1) is degraded by and promotes the production of beneficial bacteria and metabolites, which improves immune disorder and intestinal injury, and then enhances the body's immune regulation ability. However, the immune regulation effect of GP1 on a healthy body has not been studied.
View Article and Find Full Text PDFAnti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease-Reports from a Romanian Center.
Pharmaceuticals (Basel)
January 2025
Department of Paediatrics, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substantial efficacy, they are associated with a spectrum of potential adverse events (AEs). This study aims to evaluate and document these AEs to facilitate optimal patient selection and monitoring strategies of patients undergoing these therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!